Last updated: February 22, 2026
What Is the Drug Identified by NDC 60219-2651?
NDC 60219-2651 refers to Ubrogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist developed by Allergan (a division of AbbVie). Approved by the FDA for the acute treatment of migraines with or without aura in adults, Ubrogepant belongs to a class of drugs targeting migraine pathways. It was approved in October 2019 under the brand name Nurtec ODT.
Market Size and Demand Dynamics
Global Migraine Market Overview
The migraine market is valued at approximately $4.5 billion in 2023 with an expected compound annual growth rate (CAGR) of 6% through 2028 [1]. Migraine affects over 1 billion people worldwide, with a high incidence in North America and Europe.
Ubrogepant’s Position
Ubrogepant’s launch has opened a new treatment option with a favorable side effect profile compared to traditional triptans. Its ability to be used by patients with cardiovascular contraindications positions it favorably for a niche segment of the migraine population.
Market Penetration
As of 2023, Ubrogepant holds an estimated 10-15% share among prescription migraine drugs, competing with established triptans and recent CGRP monoclonal antibodies.
Pricing Overview and Historical Trends
Ubrogepant Pricing
- U.S. Wholesale Acquisition Cost (WAC): Approximately $62 per tablet (each dose is one 75 mg tablet) [2].
- Average Patient Copayment/Insurance Reimbursement: Between $20 and $35 per dose.
- Comparison With Competitors:
- Triptans: around $10–$25 per dose.
- CGRP Monoclonal Antibodies: $600–$700 monthly (administered via injection).
Price Drivers
Pricing is influenced by:
- Patent exclusivity until August 2034 [3].
- Market competition and generic entry potential.
- Expansion into additional indications (e.g., prevention).
Historical Price Trends
Since Ubrogepant’s approval, prices have remained stable with minor adjustments due to manufacturer pricing strategies and insurer negotiations. No significant discounts or rebates publicly reported as of 2023.
Regulatory and Patent Status
- Patent protection until 2034 secures exclusivity in the major markets.
- No generic versions available; patent litigation or challenges could alter the pricing landscape.
Competitive Landscape and Market Entry Risks
Key Competitors
- Triptans: Sumatriptan, Rizatriptan.
- CGRP Monoclonal Antibodies: Erenumab (Aimovig), Fremanezumab (Ajovy), Galcanezumab (Emgality).
- Other Gepants: Rimegepant (Nurtec), which has similar indications.
Market Risks
- Patent challenges could lead to generics releasing within a decade.
- Competition from oral CGRP antagonists with similar efficacy.
- Potential regulatory expansion into prophylaxis may impact market share.
Price Projection Scenarios (2023–2028)
| Scenario |
Assumptions |
Price Range (per dose) |
Key Driver |
| Conservative |
No patent challenges, modest market share growth |
$62–$70 |
Stable pricing, limited penetration |
| Moderate |
Patent holds, increased adoption, minor discounts |
$55–$62 |
Improved market reach, insurer negotiations |
| Aggressive |
Patent challenged, generic entries emerging |
$30–$45 |
Market loss, higher competition, discounting |
Projections Summary
- 2023–2025: Prices remain stable at ~$62 per dose with increased market penetration.
- 2026–2028: Potential decline to $30–$45 if patent challenges succeed or generics enter.
Key Market Factors
- Adoption rates driven by safety profile and ease of use.
- Insurance reimbursement policies influencing patient out-of-pocket costs.
- Positioning against both acute treatments and preventative options.
Conclusion
Ubrogepant, NDC 60219-2651, maintains a strong market presence due to its targeted mechanism and safety profile. Its pricing is stable, but long-term projections depend on patent enforcement and competitive dynamics. Pricing could decline significantly if patent litigation favors generics or biosimilars.
Key Takeaways
- Ubrogepant (Nurtec ODT) is a first-in-class oral CGRP antagonist for acute migraine treatment, priced at ~$62 per tablet.
- The migraine market is expanding with a CAGR of 6%, with Ubrogepant capturing a growing segment.
- Pricing stability is expected until patent expiry in 2034, after which generics may reduce costs substantially.
- Competitive threats include triptans and injectable CGRP monoclonal antibodies.
- Future pricing hinges on patent litigation outcomes, market penetration, and insurer contracts.
FAQs
Q1: How does Ubrogepant compare to triptans in efficacy?
A: Ubrogepant offers similar acute relief with a more favorable cardiovascular safety profile, especially in patients contraindicated for triptans.
Q2: What is the patent expiration date for Ubrogepant?
A: Patent protection is expected to last until August 2034 [3].
Q3: Are generic versions of Ubrogepant likely?
A: Yes, if patent challenges succeed or patent protection is invalidated, generics could enter approximately a decade after approval.
Q4: How does insurance coverage influence Ubrogepant's market?
A: Coverage varies; copay coupons and insurance policies impact patient out-of-pocket costs, affecting utilization.
Q5: What is the potential impact of new formulations or indications?
A: Expanded indications and formulations (e.g., preventative use) could bolster sales but may also introduce pricing pressures.
References
[1] MarketsandMarkets. (2023). Migraine Drugs Market.
[2] GoodRx. (2023). Nurtec ODT prices.
[3] FDA. (2022). Ubrogepant patent and exclusivity information.
[4] IQVIA. (2023). Prescription drug market analysis.
